Organization | Institute of Sera and Vaccines RAS, Moscow

Institute of Sera and Vaccines RAS, Moscow Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial

2012

NCT02787863

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2012

Timeline

NOW

Now

Active Ingredients

Drugs in Phase 4 Trials (4)

23-valent pneumococcal polysaccharide vaccine (pneumovax-23) (1 trial)

Azoximer (1 trial)

immunovac (1 trial)

pneumococcal 13-valent conjugate vaccine (prevnar 13) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Lung Diseases, Obstructive (Phase 4)

Pneumococcal Infections (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 1
# of Trial APIs: 4